Premium
Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children
Author(s) -
Huoman Johanna,
Papapavlou Georgia,
Pap Anna,
Alm Johan,
Nilsson Lennart J.,
Jenmalm Maria C.
Publication year - 2019
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1111/pai.13047
Subject(s) - medicine , sublingual immunotherapy , immunology , immune system , immunotherapy , saliva , oral immunotherapy
Background Immunomodulatory effects of sublingual immunotherapy on systemic and mucosal mediators in allergic children are largely unexplored. The aim of this study was to investigate allergy‐related cytokine and chemokine levels, as well as IgA‐responses upon a 3‐year treatment with timothy grass pollen sublingual immunotherapy in children with allergic rhinoconjunctivitis. Methods From children included in the GRAZAX ® Asthma Prevention study, blood and saliva samples were analyzed at inclusion, after 3 years of treatment, and 2 years after treatment ending. By means of Luminex and ELISA methodologies, allergy‐related cytokines and chemokines were measured in plasma samples and allergen‐stimulated peripheral blood mononuclear cell supernatants. Furthermore, studies of total, secretory, and Phl p 1–specific salivary IgA antibodies were performed using the same methods. Results GRAZAX ® ‐treated children exhibited significantly higher levels of Phl p 1–specific salivary IgA and serum IgG 4 , along with significantly lower skin prick test positivity, after 3 years of treatment and 2 years after treatment cessation. Additionally, plasma levels of the Th1‐associated chemokines CXCL10 and CXCL11 were significantly higher in treated than untreated children at these time points. Timothy‐induced ratios of IL‐5/IL‐13 over IFN‐γ were significantly decreased after 3 years with active treatment, as were symptoms of allergic rhinitis in terms of both severity and visual analogue scale scores. However, no consistent correlations were found between the clinical outcomes and immunologic parameters. Conclusion Phleum pratense sublingual immunotherapy in grass pollen allergic children modulates the immune response in the oral mucosa as well as systemically—by increasing Th1‐responses, decreasing Th2‐responses, and inducing immunoregulatory responses—all signs of tolerance induction.